Abstract
We compared the survival rates in patients with metastatic renal cell carcinoma between the cytokine and molecular targeted therapy era. The study included 321 patients who were diagnosed with metastatic renal cell carcinoma between 1987 and 2011. The patients were divided into two groups according to when they started therapy for metastatic renal cell carcinoma: in the cytokine era (1987-2007) and in the targeted therapy era (after 2008). The beginning of the follow-up period was defined as the time of discovery of metastasis occurrence. Cytokine and targeted therapy eras included 235 and 86 patients, respectively. Seventy-five percent of the patients in the cytokine era actually received cytokine therapy. Eighty-one percent of the patients in the targeted therapy era received targeted therapy and 14% received both cytokine and targeted therapy. There were no significant differences in overall survival rates (cytokine 29 months, targeted 38 months, P = 0.1789).
Highlights
Renal cell carcinoma (RCC) accounts for 2 – 3% of all malignant tumors in adults in developed countries [1]
It is difficult to set up a randomized study to evaluate survival rates in metastatic renal cell carcinoma (mRCC) patients according to the absence or presence of systemic therapy including cytokine and targeted therapy because systemic therapy is recognized as an effective measure against mRCC
The patients were divided into two groups according to the period in which they were diagnosed with mRCC: Group 1, cytokine era (1987 – 2007) and Group 2, targeted therapy era
Summary
Renal cell carcinoma (RCC) accounts for 2 – 3% of all malignant tumors in adults in developed countries [1]. We retrospectively evaluated OS in patients with mRCC and compared the results based on the treatment era, including the cytokine era and the molecular targeted therapy era. The patients were divided into two groups according to the period in which they were diagnosed with mRCC: Group 1, cytokine era (1987 – 2007) and Group 2, targeted therapy era (after 2008).
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
